Driven by a powerful combination of groundbreaking innovation and defensive appeal, the healthcare sector is witnessing a remarkable rally. In this environment, Wall Street is heavily favoring three pharmaceutical giants—Eli Lilly, Amgen, and AbbVie—each of which has seen its stock price climb more than 25% this year, significantly outpacing the S&P 500’s approximately 15.5% gain.
The sector’s strength stems from multiple factors: breakthroughs in areas like cardiovascular disease and immunology, advancements in obesity and diabetes treatments, and persistent demand from an aging global population. Furthermore, during times of economic uncertainty, healthcare stocks often serve as a safe haven, attracting risk-averse capital.
Looking ahead, Eli Lilly, Amgen, and AbbVie are well-positioned to maintain their leadership, offering investors a blend of technological moats and growth resilience.
Eli Lilly (LLY) has emerged as a standout winner, largely thanks to its GLP-1 dual-receptor agonist, Tirzepatide. Marketed as Mounjaro for diabetes and Zepbound for weight loss, the drug generated $24.8 billion in sales over the first three quarters, surpassing Merck’s blockbuster cancer drug Keytruda to become the world’s top-selling pharmaceutical product.
Amid an explosive expansion of the GLP-1 market, Eli Lilly has captured a dominant 57% market share in the second quarter, outperforming rival Novo Nordisk. The company is now developing an oral version of its GLP-1 receptor agonist (current products are injectable), with plans to seek global regulatory approval by the end of 2025. Bolstered by these catalysts, Eli Lilly’s stock has surged 27% year-to-date.
Biotech firm Amgen (AMGN) has demonstrated robust performance, reporting third-quarter revenue and profit that exceeded expectations, with product sales jumping 12% year-over-year. The company’s strength lies in its diverse product lineup, which includes stars like the inflammatory disease treatment Uplizna, the sinusitis and asthma therapy Tezspire, and the osteoporosis drug Prolia. Additionally, its cholesterol-lowering drug Repatha recently confirmed it can reduce the risk of a first heart attack by 36%.
This strong operational performance has propelled Amgen’s stock upward, with a 26% gain for the year, including an 11% surge in the past week alone.
AbbVie (ABBV) has become a new darling on Wall Street, powered by significant advances in neuroscience and immunology. Its depression treatment Vraylar, along with migraine therapies Ubrelvy and Qulipta, provides steady growth, while immunology drugs Skyrizi and Rinvoq act as primary engines. The company projects that Rinvoq will achieve annual revenue of $11 billion by 2027, with Skyrizi expected to surpass $20 billion. Strong market confidence in this outlook has driven AbbVie’s shares 25% higher this year.
